Ionis Pharmaceuticals ( (IONS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ionis Pharmaceuticals’ share weakness comes as investors grow cautious about increased insider selling, which has clouded sentiment despite otherwise improving fundamentals. Analysts have actually turned more optimistic on the company, pointing to progress in late-stage drug programs and encouraging Phase 3 and partner trial results, and recent quarterly numbers showed revenue climbing with a narrower GAAP loss versus last year. These factors have led some on Wall Street to lift their outlooks on the stock, even as the insider activity weighs on near‑term trading.
More about Ionis Pharmaceuticals
YTD Price Performance: -2.40%
Average Trading Volume: 2,328,097
Technical Sentiment Signal: Buy
Current Market Cap: $12.77B
For further insights into IONS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.